PSMA-007-001
14 Sep 2023
Trial Summary
This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 administered as a single agent in adults with metastatic castration-resistant prostate cancer (mCRPC).
Acronym:
PSMA-007-001
ACTRN/NCT /ethics:
NCT05519449
Scientific title:
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
Sponsor / Cooperative group:
Janux Therapeutics
Trial & Patient Characteristics
| Cancer Type | Prostate |
|---|---|
| Trial Type | Treatment |
| Phase | Phase I |
| Age Range | 18 years and older |
| Sex | - |
| Tumour Stream | - |
| Cancer Stage | - |
| Anticipated Start Date | 2022-09-15 |
| Anticipated End Date | 2025-03-01 |
Participating Hospitals
| Hospital | Southern Oncology Clinical Research Unit |
|---|---|
| Clinical Trial Coordinator | Meggan O'Riley |
| Meggan.Oriley@socru.org.au | |
| Phone | 0491 679 039 |
| Principal Investigator | Ganessan Kichenadasse |
| Recruitment Status | Recruiting |